RESUMEN
Among the flaviviruses, dengue, with its four serotypes, has spread throughout the tropics. The most advanced vaccines developed so far include live attenuated viruses, which have been tested in humans but none has been licensed. Preclinical testing of dengue vaccine candidates is performed initially in mice and in nonhuman primates. In the latter the main criteria used to assay protection are neutralizing antibodies elicited by the vaccine candidate and the magnitude and duration of peripheral viremia upon challenge of previously immunized animals. Towards the identification of wild-type viruses that could be used in challenge experiments a total of 31 rhesus monkeys were inoculated subcutaneously of wild dengue types 1, 2, and 3 viruses. The viremia caused by the different viruses was variable but it was possible to identify dengue viruses useful as challenge strains.
Asunto(s)
Virus del Dengue , Dengue/virología , Viremia/virología , Animales , Chlorocebus aethiops , Dengue/prevención & control , Vacunas contra el Dengue/uso terapéutico , Virus del Dengue/clasificación , Virus del Dengue/inmunología , Virus del Dengue/patogenicidad , Modelos Animales de Enfermedad , Femenino , Humanos , Macaca mulatta/virología , Masculino , Células Vero/virologíaRESUMEN
Among the flaviviruses, dengue, with its four serotypes, has spread throughout the tropics. The most advanced vaccines developed so far include live attenuated viruses, which have been tested in humans but none has been licensed. Preclinical testing of dengue vaccine candidates is performed initially in mice and in nonhuman primates. In the latter the main criteria used to assay protection are neutralizing antibodies elicited by the vaccine candidate and the magnitude and duration of peripheral viremia upon challenge of previously immunized animals. Towards the identification of wild-type viruses that could be used in challenge experiments a total of 31 rhesus monkeys were inoculated subcutaneously of wild dengue types 1, 2, and 3 viruses. The viremia caused by the different viruses was variable but it was possible to identify dengue viruses useful as challenge strains.
Asunto(s)
Humanos , Animales , Masculino , Femenino , Virus del Dengue/clasificación , Virus del Dengue/patogenicidad , Viremia/virología , Chlorocebus aethiops , Modelos Animales de Enfermedad , Macaca mulatta/virología , Células Vero/virologíaRESUMEN
A chimeric yellow fever (YF)-dengue serotype 2 (dengue 2) virus was constructed by replacing the premembrane and envelope genes of the YF 17D virus with those from dengue 2 virus strains of Southeast Asian genotype. The virus grew to high titers in Vero cells and, after passage 2, was used for immunogenicity and attenuation studies in rhesus monkeys. Subcutaneous immunization of naive rhesus monkeys with the 17D-D2 chimeric virus induced a neutralizing antibody response associated with the protection of 6 of 7 monkeys against viremia by wild-type dengue 2 virus. Neutralizing antibody titers to dengue 2 were significantly lower in YF-immune animals than in YF-naive monkeys and protection against challenge with wild-type dengue 2 virus was observed in only 2 of 11 YF-immune monkeys. An anamnestic response to dengue 2, indicated by a sharp increase of neutralizing antibody titers, was observed in the majority of the monkeys after challenge with wild-type virus. Virus attenuation was demonstrated using the standard monkey neurovirulence test. The 17D-D2 chimera caused significantly fewer histological lesions than the YF 17DD virus. The attenuated phenotype could also be inferred from the limited viremias compared to the YF 17DD vaccine. Overall, these results provide further support for the use of chimeric viruses for the development of a new live tetravalent dengue vaccine.
Asunto(s)
Animales , Masculino , Femenino , Anticuerpos Antivirales/biosíntesis , Viremia/inmunología , Virus del Dengue/inmunología , Virus de la Fiebre Amarilla/inmunología , Secuencia de Aminoácidos , Anticuerpos Antivirales/inmunología , Chlorocebus aethiops , Macaca mulatta , Datos de Secuencia Molecular , Pruebas de Neutralización , Recombinación Genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Vero , Virus del Dengue/genética , Virus de la Fiebre Amarilla/genéticaRESUMEN
A chimeric yellow fever (YF)-dengue serotype 2 (dengue 2) virus was constructed by replacing the premembrane and envelope genes of the YF 17D virus with those from dengue 2 virus strains of Southeast Asian genotype. The virus grew to high titers in Vero cells and, after passage 2, was used for immunogenicity and attenuation studies in rhesus monkeys. Subcutaneous immunization of naive rhesus monkeys with the 17D-D2 chimeric virus induced a neutralizing antibody response associated with the protection of 6 of 7 monkeys against viremia by wild-type dengue 2 virus. Neutralizing antibody titers to dengue 2 were significantly lower in YF-immune animals than in YF-naive monkeys and protection against challenge with wild-type dengue 2 virus was observed in only 2 of 11 YF-immune monkeys. An anamnestic response to dengue 2, indicated by a sharp increase of neutralizing antibody titers, was observed in the majority of the monkeys after challenge with wild-type virus. Virus attenuation was demonstrated using the standard monkey neurovirulence test. The 17D-D2 chimera caused significantly fewer histological lesions than the YF 17DD virus. The attenuated phenotype could also be inferred from the limited viremias compared to the YF 17DD vaccine. Overall, these results provide further support for the use of chimeric viruses for the development of a new live tetravalent dengue vaccine.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Virus del Dengue/inmunología , Viremia/inmunología , Virus de la Fiebre Amarilla/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Antivirales/inmunología , Chlorocebus aethiops , Virus del Dengue/genética , Femenino , Macaca mulatta , Masculino , Datos de Secuencia Molecular , Pruebas de Neutralización , Recombinación Genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Vero , Virus de la Fiebre Amarilla/genéticaRESUMEN
Chimeric yellow fever (YF)-dengue type 2 (Den 2) viruses were constructed by replacing the premembrane (prM) and envelope (E) genes of YF 17D virus with those from Den 2 virus strains of south-east Asian genotype. Whereas viable chimeric viruses were successfully recovered when the YF 17D C gene and the Den 2 prM gene were fused at the signalase cleavage site, no virus could be rescued from the constructions fused at the viral protease cleavage site. Unlike YF virus that replicated in all the cell lines tested and similar to the Den 2 virus, the recombinant viruses did not replicate in vaccine-production certified CEF and MRC5 cells. Besides, chimeric 17D/Den 2 viruses and their parental viruses reached similar growth titers in Vero and C6/36 cell cultures. Analysis of mouse neurovirulence, performed by intracerebral inoculation, demonstrated that the 17D/Den 2 chimera is more attenuated in this system than the YF 17DD virus. Immunization of mice with this chimera induced a neutralizing antibody response associated with a partial protection against an otherwise lethal dose of mouse neurovirulent Den 2 NGC virus. Overall, these results provide further support for the use of chimeric viruses as an attractive methodology for the development of new live flavivirus vaccines.
Asunto(s)
Virus del Dengue/genética , Virus de la Fiebre Amarilla/genética , Secuencia de Aminoácidos , Animales , Chlorocebus aethiops , Virus del Dengue/crecimiento & desarrollo , Virus del Dengue/inmunología , Virus del Dengue/patogenicidad , Electroforesis en Gel de Poliacrilamida/métodos , Ratones , Datos de Secuencia Molecular , Recombinación Genética , Análisis de Secuencia de ADN , Células Vero , Proteínas Virales/análisis , Virus de la Fiebre Amarilla/crecimiento & desarrollo , Virus de la Fiebre Amarilla/inmunología , Virus de la Fiebre Amarilla/patogenicidadRESUMEN
The yellow fever (YF) 17D virus is one of the most successful vaccines developed to data. Its use has been estimated to be over 400 million doses with an excellent record of safety. In the past 3 years, yellow fever vaccination was intensified in Brazil in response to higher risk of urban outbreaks of the disease. Two fatal adverse events temporally associated with YF vaccination were reported. Both cases had features similar to yellow fever disease, including hepatitis and multiorgan failure. Two different lots of YF 17DD virus vaccine were administered to the affected patients and also to hundreds of thousands of other individuals without any other reported serious adverse events. The lots were prepared from the secondary seed, which has been in continuous use since 1984. Nucleotide sequencing revealed minor variations at some nucleotide positions between the secondary seed lot virus and the virus isolates from patients; these differences were not consistent across the isolates, represented differences in the relative amount of each nucleotide in a heterogeneous position, and did not result in amino acid substitutions. Inoculation of rhesus monkeys with the viruses isolated from the two patients by the intracerebral (ic) or intrahepatic (ih) route caused minimal viremia and no clinical signs of infection or alterations in laboratory markers. Central nervous system histological scores of rhesus monkeys inoculated ic were within the expected range, and there were no histopathological lesions in animals inoculated ih. Altogether, these results demonstrated the genetic stability and attenuated phenotype of the viruses that caused fatal illness in the two patients. Therefore, the fatal adverse events experienced by the vaccinees are related to individual, genetically determined host factors that regulate cellular susceptibility to yellow fever virus. Such increased susceptibility, resulting in clinically overt disease expression, appears to be extremely rare.
Asunto(s)
Vacuna contra la Fiebre Amarilla/genética , Fiebre Amarilla/virología , Virus de la Fiebre Amarilla/genética , Animales , Anticuerpos Antivirales/sangre , Brasil , Chlorocebus aethiops , Seguridad de Productos para el Consumidor , Modelos Animales de Enfermedad , Femenino , Humanos , Macaca mulatta , Masculino , Fenotipo , Análisis de Secuencia de ADN , Vacunación , Células Vero , Viremia , Fiebre Amarilla/prevención & control , Vacuna contra la Fiebre Amarilla/efectos adversos , Virus de la Fiebre Amarilla/crecimiento & desarrollo , Virus de la Fiebre Amarilla/fisiologíaRESUMEN
OBJECTIVES: To compare seroconversion rates induced by Biken CAM-70 measles vaccines at different viral concentrations. METHODS: Healthy children aged 9 to 18 months from a primary health care unit in Rio de Janeiro, Brazil, and whose guardians agreed with their participation, were randomly assigned to receive one of the following vaccine formulations: 5,000, 1,000 or 200 CCID50 (50% Tissue Culture Infective Dose). The research team, participants, and data analysts were blinded to the type of vaccine administered. Pre- and post-vaccination antibody levels were assessed through Plaque Reduction Neutralization Test. Two interim data analyses were planned to assess unequivocal evidence of the superiority of one of the vaccine types. RESULTS: From 223 recruited children, 84% completed the whole course. Of them, 79% were less than 10 months of age, and 93% did not show detectable measles antibodies in pre-vaccination serum. Seroconversion (four-fold increase in antibody levels) in groups vaccinated with 5,000, 1,000 or 200 CCID50, were 82%, 55%, and 37% (p<0.0000), respectively. Differences in the mean concentration of post-vaccination antibodies were also substantial and statistically significant (p<0.000). Seroconversion rates (pooling data from all vaccine formulations) were 73% to children aged 10 months or more, and 53% in those below 10 months. CONCLUSIONS: Vaccines with concentrations below 5,000 CCID50 did not produce satisfactory seroconversion rates. The vaccine performance by age was consistent with that seen in other studies using Biken CAM-70 strain in which a sizable proportion of 9-month-old children failed to achieve full immunological response.
Asunto(s)
Vacuna Antisarampión/inmunología , Sarampión/prevención & control , Análisis de Varianza , Anticuerpos Antivirales/sangre , Composición de Medicamentos , Femenino , Humanos , Lactante , Masculino , Sarampión/inmunología , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/efectos adversos , Proyectos de Investigación , Pruebas SerológicasRESUMEN
In order to determine whether previous measles vaccination interferes with the sero-response to yellow fever vaccine, 294 children at nine months of age were randomly assigned to immunization with yellow fever vaccine at different time intervals after measles vaccination. The seroconversion rate (SCR) and the log10 geometric mean titer (GMT) for 17 DD yellow fever vaccine at different intervals after Schwarz measles vaccination were: 1-6 days: SCR = 44/57 = 77%; GMT = 4.57; 7-13 days: SCR = 36/53 = 68%; GMT = 4.46; 14-21 days: SCR = 55/65 = 85%; GMT = 4.46; 22-27 days: SCR = 41/54 = 76%; GMT = 4.41 and >28 days: SCR = 52/65 = 80%; GMT = 4.24 (p > 0.05). We conclude that recent immunization against measles does not interfere with the sero-response to yellow fever vaccine.
Asunto(s)
Vacuna Antisarampión/inmunología , Sarampión/prevención & control , Vacunas Virales/inmunología , Fiebre Amarilla/prevención & control , Virus de la Fiebre Amarilla/inmunología , Anticuerpos Antivirales/biosíntesis , Brasil , Niño , Ensayo de Inmunoadsorción Enzimática , Humanos , Vacunación , Vacunas AtenuadasRESUMEN
Trivalent virus vaccine, containing measles AIK-C strain, mumps Hoshino strain, and rubella Takahashi strain, was administered to a total of 1369 healthy children, 8 months to 18 years of age. For comparative study, monovalent vaccines of AIK-C strain and Hoshino strain were administered to 147 and 122 initially seronegative children, respectively. The clinical and serological responses following vaccination were analyzed. Among the recipients of the trivalent vaccine, 893 were initially seronegative to all three viruses. Inoculation induced sufficient serological responses: 99.7% for measles and rubella viruses and 96.3% for mumps virus. The incidence of febrile reaction (greater than or equal to 37.5 degrees C axillary temperature) was low, 15.9%, and a temperature of 39.0 degrees C or higher occurred in only 1.3% of the subjects. The seroconversion rate, magnitude of antibody titers, and incidence of clinical reactions following the trivalent vaccination were similar to those occurring after the monovalent measles vaccination.
Asunto(s)
Vacuna Antisarampión/normas , Vacuna contra la Parotiditis/normas , Vacuna contra la Rubéola/normas , Adolescente , Formación de Anticuerpos , Preescolar , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta Inmunológica , Quimioterapia Combinada/normas , Humanos , Lactante , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/inmunología , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Parotiditis/inmunología , Vacuna contra la Rubéola/administración & dosificación , Vacuna contra la Rubéola/inmunologíaRESUMEN
A trivalent measles-mumps-rubella live virus vaccine, containing measles AIK-C strain, mumps Hoshino strain, and rubella Takahashi strain, was evaluated in 229 children, aged 1 to 5 years. The vaccine induced a high seroconversion rate: 221 (98.7%) out of 224 subjects initially seronegative for measles virus, 167 (93.3%) out of 179 initially seronegative for mumps virus, and 212 (99.1%) out of 214 initially seronegative for rubella virus. It also induced a sufficient cellular immunity against each of the three viruses in over 90% of the subjects, as judged by virus-specific interferon-gamma (IFN-gamma) production. Virus-specific IFN-gamma production was observed 10 days after vaccination by stimulation with measles virus and rubella virus and 14 days after vaccination by stimulation with mumps virus. Mumps-virus-specific IFN-gamma production was observed in 7 out of 12 recipients without seroconversion for mumps virus. And measles-virus-specific IFN-gamma production was demonstrated in one out of three recipients without seroconversion for measles virus. A significant correlation was observed between the serum antibody and IFN-gamma production six weeks after vaccination for measles virus (r = 0.201, P less than 0.01) and for mumps virus (r = 0.174, P less than 0.05) but not for rubella virus (r = -0.045, P less than 0.05). The incidence of febrile reactions of greater than or equal to 37.5 C was quite low, 14.4%, and that of greater than or equal to 39 C occurred in only 1.3% of the recipients. These results suggested that the trivalent vaccine induced sufficient humoral and cellular immunity and yet resulted in no more untoward reaction than observed from the measles vaccine alone.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Interferón gamma/biosíntesis , Vacuna Antisarampión/administración & dosificación , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Rubéola/administración & dosificación , Preescolar , Combinación de Medicamentos , Estudios de Evaluación como Asunto , Hemaglutinación por Virus/efectos de los fármacos , Humanos , Lactante , Linfocitos/inmunología , Sarampión/prevención & control , Vacuna Antisarampión/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas/prevención & control , Vacuna contra la Parotiditis/inmunología , Rubéola (Sarampión Alemán)/prevención & control , Vacuna contra la Rubéola/inmunología , VacunaciónRESUMEN
Soros obtidos de pacientes com quadro clinico compativel com rubeola, coletados em intervalos variados em relacao ao inicio do exantema, foram comparados em seu conteudo de anticorpos para esta virose, da classe IgM, pelas tecnicas de ultracentrifugacao em gradiente de sacarose, proteina A utilizando amostra de Staphylococcus aureus e pelo metodo imunoenzimatico (Elisa). Verificou-se que o metodo de ultracentrifugacao apresenta maior sensibilidade, em relacao aos outros metodos, com resultados positivos dentro da primeira semana de doenca e ate a 6a. semana. Os melhores resultados com os metodos da proteina A e imunoenzimatico foram observados com os soros coletados entre 2 a 3 semanas apos o exantema